APRIL (AbatacePt in Rheumatoid Arthritis-ILD)

Last updated: July 18, 2019
Sponsor: Cambridge University Hospitals NHS Foundation Trust
Overall Status: Active - Recruiting

Phase

2

Condition

Arthritis And Arthritic Pain

Rheumatoid Arthritis

Joint Injuries

Treatment

N/A

Clinical Study ID

NCT03084419
APRIL
  • Ages > 18
  • All Genders

Study Summary

Early initiation of treatment for Rheumatoid arthritis (RA) can prevent several of the long term problems associated with the condition. However, many RA patients develop lung inflammation and scarring, called 'interstitial lung disease' (RA-ILD), contributing to early death in 1 in 5 people. There is no proven treatment for these patients and some medications for RA can in fact worsen their lung disease. There is a need therefore to find safe medications that can not only control RA joint disease, but also prevent progression of RA-ILD. Abatacept is an approved drug for treating RA and is used widely. It is a newer RA medication, with a unique mechanism of action, and it has been shown to prevent progression of joint damage and improve physical function. The investigators aim to assess the safety of this medication in patients with RA-ILD and improve our understanding of the mechanism of lung damage in rheumatoid disease.

The investigators will perform a small clinical trial to assess the feasibility of performing a larger randomized controlled trial. A total of 30 patients with RA-ILD will be treated with abatacept infusions fortnightly for the first month, then every 4 weeks for a total of 20 weeks. In order to be eligible for the study, a patient must be able to provide written informed consent, be aged ≥18 years, and have interstitial lung disease that has not responded to or progressed over 6 months despite conventional immunosuppression. Change in lung function (forced vital capacity) at 24 weeks will be evaluated. To assess the mechanisms that may be involved with the development of ILD, the investigators will assess the effects of abatacept on biomarkers obtained from the blood and the lung (bronchoalveolar lavage), including markers of infection (the lung microbiome).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Aged 18 years or over

  • Agree to use 2 acceptable forms of effective contraception for the duration of thestudy trial and a further 14 weeks after completion

  • Meet a diagnosis of RA by 2010 EULAR/ACR criteria

  • Have interstitial lung disease associated with RA, with supportive findings on theirPFTs and CT Chest scans. Participants will be included if their ILD has progressedover 14 months. Progression will be defined as EITHER:

  • A decrease in FVC by at least 5% when comparing two sets of PFTs done in the last 24months, but with an interval of up to 14 months between the PFTs OR

  • Progression of lung fibrosis on a high-resolution CT chest, as reported by a chestradiologist.

Exclusion

Exclusion Criteria:

  • Unable to provide informed written consent

  • Participants who are taking other immunosuppressants, e.g. mycophenolate mofetil (MMF), unless this has been discontinued with an adequate washout period. Theexceptions to this exclusion criterion are methotrexate (MTX) and hydroxychloroquine,which are allowed provided the dose has been stable for 6 weeks prior to baseline (visit 2).

  • Participants who have been taking > 10mg Prednisolone daily within the last 6 weeksprior to baseline (visit 2)

  • Participants who have had rituximab, within the 24 weeks prior to baseline (Visit 2)

  • Any participant with active signs or symptoms of infection at the baseline (visit 2)or requiring antibiotic treatment within the preceding 4 weeks

  • Any participant with significant co-existing lung disease, such as asthma,bronchiectasis, emphysema, Chronic Obstructive Pulmonary Disease (COPD) or if theirpre-bronchodilator FEV1/FVC ratio is < 60%.

  • Significant other co-morbidity (e.g. active malignancy/liver disease/renal disease)within the last 5 years

  • Prior use of abatacept at any time

  • Participation in any other clinical trial within 8 weeks or 5 half-lives of IMP,whichever is longer, prior to baseline (visit 2) (participation in 'observational'studies is allowed)

  • Hypersensitivity to any excipients of abatacept

  • Any participant who has had live vaccines within 6 weeks prior to baseline (Visit 2)

  • Participant is pregnant or breastfeeding

Study Design

Total Participants: 30
Study Start date:
June 26, 2018
Estimated Completion Date:
March 01, 2020

Connect with a study center

  • Addenbrookes Hospital

    Cambridge, CB2 0QQ
    United Kingdom

    Active - Recruiting

  • Papworth Hospital

    Cambridge, CB23 3RE
    United Kingdom

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.